BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 225 filers reported holding BRIDGEBIO PHARMA INC in Q3 2023. The put-call ratio across all filers is 0.81 and the average weighting 0.6%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,994,653 | +150.7% | 75,641 | +63.5% | 0.00% | +200.0% |
Q2 2023 | $795,724 | -65.0% | 46,263 | -66.2% | 0.00% | -66.7% |
Q1 2023 | $2,270,514 | +616.6% | 136,943 | +229.4% | 0.00% | – |
Q4 2022 | $316,824 | -23.3% | 41,578 | 0.0% | 0.00% | -100.0% |
Q3 2022 | $413,285 | +9.3% | 41,578 | 0.0% | 0.00% | 0.0% |
Q2 2022 | $378,000 | -10.4% | 41,578 | 0.0% | 0.00% | 0.0% |
Q1 2022 | $422,000 | -39.2% | 41,578 | 0.0% | 0.00% | 0.0% |
Q4 2021 | $694,000 | -64.8% | 41,578 | -1.1% | 0.00% | -75.0% |
Q3 2021 | $1,971,000 | -23.7% | 42,060 | -0.8% | 0.00% | -20.0% |
Q2 2021 | $2,583,000 | +1.6% | 42,379 | +2.7% | 0.01% | 0.0% |
Q1 2021 | $2,543,000 | +12.9% | 41,278 | +30.3% | 0.01% | 0.0% |
Q4 2020 | $2,253,000 | +139.7% | 31,688 | +26.5% | 0.01% | +150.0% |
Q3 2020 | $940,000 | +12.0% | 25,042 | -2.6% | 0.00% | 0.0% |
Q2 2020 | $839,000 | -21.9% | 25,717 | -30.6% | 0.00% | -33.3% |
Q1 2020 | $1,074,000 | +182.6% | 37,038 | +241.7% | 0.00% | +200.0% |
Q4 2019 | $380,000 | – | 10,839 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aisling Capital Management LP | 6,068,125 | $55,099,000 | 39.31% |
M28 Capital Management LP | 466,200 | $4,233,000 | 4.74% |
Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $282,034,000 | 3.75% |
Octagon Capital Advisors LP | 933,743 | $8,478,000 | 2.26% |
VIKING GLOBAL INVESTORS LP | 26,620,991 | $241,719,000 | 1.11% |
HHLR ADVISORS, LTD. | 5,362,014 | $48,687,000 | 1.04% |
Cormorant Asset Management, LP | 1,469,179 | $13,340,000 | 1.01% |
Knott David M Jr | 213,206 | $1,936,000 | 0.81% |
Fernwood Investment Management, LLC | 183,900 | $1,670,000 | 0.72% |
HighVista Strategies LLC | 105,942 | $962,000 | 0.58% |